Protocadherin B9 promotes resistance to bicalutamide and is associated with the survival of prostate cancer patients

Overexpression of PCDHB9 promotes peritoneal metastasis and correlates with poor prognosis in patients with gastric cancer

(2017) Shoichiro Mukai et al.   JOURNAL OF PATHOLOGY

Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer

(2017) Chengfei Liu et al.   MOLECULAR CANCER THERAPEUTICS

Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery

(2017) Kieran J. Breen et al.   PROSTATE

KIFC1 induces resistance to docetaxel and is associated with survival of patients with prostate cancer

(2017) Yohei Sekino et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

 v 6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor

(2016) H. Lu et al.   CANCER RESEARCH

Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data

(2016) Claire L Vale et al.   LANCET ONCOLOGY

Understanding heterogeneity of treatment effect in prostate cancer

(2015) Abdalla Aly et al.   CURRENT OPINION IN ONCOLOGY

Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level

(2015) Theodoros Karantanos et al.   EUROPEAN UROLOGY

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer

(2015) Christopher J. Sweeney et al.   NEW ENGLAND JOURNAL OF MEDICINE

The transcribed-ultraconserved regions in prostate and gastric cancer: DNA hypermethylation and microRNA-associated regulation

(2015) K Goto et al.   ONCOGENE

Cross Modulation between the Androgen Receptor Axis and Protocadherin-PC in Mediating Neuroendocrine Transdifferentiation and Therapeutic Resistance of Prostate Cancer

(2015) Stéphane Terry et al.   NEOPLASIA

Integrin  v 6 Promotes an Osteolytic Program in Cancer Cells by Upregulating MMP2

(2014) A. Dutta et al.   CANCER RESEARCH

Aberrant Methylation of PCDH10 Predicts Worse Biochemical Recurrence-Free Survival in Patients with Prostate Cancer After Radical Prostatectomy

(2014) Wen-Ping Li   MEDICAL SCIENCE MONITOR

Clustered protocadherins

(2013) W. V. Chen et al.   DEVELOPMENT

Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy

(2013) Alberto Briganti et al.   EUROPEAN UROLOGY

Prognostic prediction following radical prostatectomy for prostate cancer using conventional as well as molecular biological approaches

(2012) Hideaki Miyake et al.   INTERNATIONAL JOURNAL OF UROLOGY

Epigenetic inactivation ofPCDH10in human prostate cancer cell lines

(2011) Zesong Li et al.   CELL BIOLOGY INTERNATIONAL

Biomarkers in the Management and Treatment of Men with Metastatic Castration-Resistant Prostate Cancer

(2011) Andrew J. Armstrong et al.   EUROPEAN UROLOGY

The Epigenetic promise for prostate cancer diagnosis

(2011) Leander Van Neste et al.   PROSTATE

Non-clustered protocadherin

(2011) Soo-Young Kim et al.   Cell Adhesion & Migration

Integrins and bone metastasis: Integrating tumor cell and stromal cell interactions

(2010) Jochen G. Schneider et al.   BONE

Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2

(2009) S. Feng et al.   MOLECULAR CANCER THERAPEUTICS

Integrins in prostate cancer progression

(2008) H. L. Goel et al.   ENDOCRINE-RELATED CANCER